Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes

European Journal of Clinical Pharmacology

Volumn 58, Issue 12, 2003, Pages 791-794

  Lee, Craig R ^a   Pieper, John A ^a   Frye, Reginald F ^b   Hinderliter, Alan L ^c   Blaisdell, Joyce A ^d   Goldstein, Joyce A ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

CYP2C9; Flurbiprofen; Polymorphisms

Indexed keywords

4' HYDROXYFLURBIPROFREN; CYTOCHROME P450 2C9; DRUG METABOLITE; FLURBIPROFEN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 0038293267     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0574-6     Document Type: Article

References (21)

1. Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538
2. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12:251-263
3. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429-439
4. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349
5. Bhasker CR, Miners JO, Coulter S, Birkett DJ (1997) Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7:51-58
6. Aithal GP, Day CP, Kesteven PJL, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719
7. van der Weide J, Steijns LS, van Weelden MJ, de Haan K (2001) The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11:287-291
8. Hutzler JM, Frye RF, Tracy TS (2000) Sensitive and specific high-performance liquid chromatographic assay for 4′-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. J Chromatogr B Biomed Appl 749:119-125
9. Caraco Y, Muszkat M, Wood AJJ (2001) Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11:587-596
10. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meise C, et al (2002) Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101-109
11. Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, et al (2002) Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12:111119
12. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA (2002) Evaluation of CYP2C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes. Clin Pharmacol Ther 72:562-571
13. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286-296
14. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, et al (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89-98
15. Morin S, Loriot MA, Poirier JM, Tenneze L, Beaune PH, Funck-Brentano C, et al (2001) Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 56:793-797
16. Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjoqvist F, et al (2001) The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 57:729-735
17. 359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95-104
18. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR (1995) Role of cytochrome P4502C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 49:1269-1275
19. Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers (1995) Clin Pharmacokinet 28:100-114
20. Frye RF, Tracy TS, Hutzler JM, Korzekwa KR, Cannon Y, Pauli M, et al (2000) Flurbiprofen as a selective in vivo probe of CYP2C9 activity. Clin Pharmacol Ther 67:109 [abstract]
21. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90